CSLLY News and Press, CSL Ltd ADR From 04/24/24

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...

2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...

2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...

2024-03-07 13:29:15 ET More on AstraZeneca, CSL, etc. Sanofi (SNY) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgr...

2024-03-07 09:19:59 ET More on CSL CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgrade) CSL Limited (CSLLY) Q2 2024 Earnings Call Transcript CSL Limited falls after Phase 3 setback for key trial Historical earnings data for CSL ...

CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season PR Newswire SUMMIT, N.J. , March 6, 2024 /PRNewswire/ -- CSL Seqirus, a glob...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission dec...

2024-02-23 07:05:14 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics Q4 2023 Earnings Preview Travere inks licensing deal for sparsen...